Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.88 |
| ▸ | HTT | P42858 | 2/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | POLB | P06746 | 1/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.79 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303527 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL699639 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL4537086 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8200466 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL565301 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8203532 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL10724066 | 1.00 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8502340 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8583228 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL7953663 | 0.94 | PKM (1.00) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190276416-A1 | METHOD FOR PREPARING NOTA DERIVATIVE | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2019-09-12 | — | — | US | claimed |
| US-5326861-A | Cyclization | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1994-07-05 | — | — | US | claimed |
| EP-3176155-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | CATEXEL LTD (GB) | 2019-09-25 | — | — | EP | disclosed |
| US-20190276416-A1 | METHOD FOR PREPARING NOTA DERIVATIVE | Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R.O.C. (TW) | 2019-09-12 | — | — | US | disclosed |
| US-9988388-B2 | Synthesis of imidazo[1,2-a]pyrazin-4-ium salts for the synthesis of 1,4,7-triazacyclononane (tacn) and N- and/or C- functionalized derivatives thereof | UNIVERSITE DE BOURGOGNE (FR) | 2018-06-05 | — | — | US | disclosed |
| US-9981967-B2 | Synthesis of imidazo[1,2-a]pyrazin-4-ium salts for the synthesis of 1,4,7-triazacyclononane (tacn) and N- and/or C-functionalized derivatives thereof | UNIVERSITE DE BOURGOGNE (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-3176155-A1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE FOR THE SYNTHESIS OF SAME | Catexel Limited (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-2590952-B1 | 1,2-BIS-(4,7-DIMETHYL-1,4,7-TRIAZACYCLONON-1-YL)-ETHANE AND INTERMEDIATE THEREOF | CATEXEL LTD (GB) | 2017-01-18 | — | — | EP | disclosed |
| US-20160222018-A1 | SYNTHESIS OF IMIDAZO[1,2-a]PYRAZIN-4-IUM SALTS FOR THE SYNTHESIS OF 1,4,7-TRIAZACYCLONONANE (TACN) AND N- AND/OR C- FUNCTIONALIZED DERIVATIVES THEREOF | UNIVERSITE DE BOURGOGNE (FR) | 2016-08-04 | — | — | US | disclosed |
| US-20160222018-A1 | SYNTHESIS OF IMIDAZO[1,2-a]PYRAZIN-4-IUM SALTS FOR THE SYNTHESIS OF 1,4,7-TRIAZACYCLONONANE (TACN) AND N- AND/OR C- FUNCTIONALIZED DERIVATIVES THEREOF | UNIVERSITE DE BOURGOGNE (FR) | 2016-08-04 | — | — | US | disclosed |
| CN-104529922-A | Preparation method of 1,4,7-triazacyclononane hydrochloride | SHENZHEN RES INST OF THE PHOTOGRAPHIC MATERIALS & CHEMICAL INDUSTRY | 2015-04-22 | — | — | CN | disclosed |
| US-5874573-A | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy | CONCAT, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0841951-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS, AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT LTD. (US) | 1998-05-20 | — | — | EP | disclosed |
| US-5739022-A | CLEAVAGE PHOSPHORUS, OXYGEN LINKAGE FO NUCLEIC ACIDS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997001360-A9 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | — | 1997-07-17 | — | — | WO | disclosed |
| WO-1997001360-A2 | COMPOUNDS WITH CHELATION AFFINITY AND SELECTIVITY FOR FIRST TRANSITION SERIES ELEMENTS AND THEIR USE IN MEDICAL THERAPY AND DIAGNOSIS | CONCAT, LTD. (US) | 1997-01-16 | — | — | WO | disclosed |
| US-5326861-A | Cyclization | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| US-5326861-A | Cyclization | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| WO-1994008981-A1 | PREPARATION OF ORGANIC MACROCYCLIC COMPOUNDS | UNILEVER PLC (GB) | 1994-04-28 | — | — | WO | disclosed |
| WO-1994008981-A1 | PREPARATION OF ORGANIC MACROCYCLIC COMPOUNDS | UNILEVER PLC (GB) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222018-A1 | SYNTHESIS OF IMIDAZO[1,2-a]PYRAZIN-4-IUM SALTS FOR THE SYNTHESIS OF 1,4,7-TRIAZACYCLONONANE (TACN) AND N- AND/OR C- FUNCTIONALIZED DERIVATIVES THEREOF | TAC3, TACR2, TACR3 | PKM 627/4885HTT 2718/4885ALDH1A1 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.